JAK inhibitors use in immune-mediated inflammatory diseases not tied to thromboembolic risk
An article published in Rheumatology has concluded that JAK inhibitors are not tied to an increased risk of thromboembolic than placebo in immune-mediated inflammatory diseases or IMIDs patients.
Based on Preliminary data, clinicians have been warned regarding the increased venous thrombotic risk associated with using JAK inhibitors (JAKi).
This was further investigated by researchers in the present study using databases from MEDLINE and EMBASE.
The study summary includes the following essential considerations:
- There were 19443 patients in the JAKi group and 6354 in the control group.
- In the JAKi and control group, Thirty-one and 20 events were reported.
- The mean follow-up duration was of 16.8 weeks.
- There was no thromboembolic risk among IMIDs patients treated with JAKi compared to placebo.
They said, “JAKi do not increase thromboembolic risk in IMIDs patients.”
The study limitations were related to the non-reporting of cardiovascular events and underestimation.
Further reading:
Francesco Campanaro and others, Venous and arterial thromboembolic risk of JAK inhibitors: a systematic review with meta-analysis, Rheumatology, 2023; kead211, https://doi.org/10.1093/rheumatology/kead211
